PRCT250117C97500
- 0.50
- +0.35+233.33%
PROCEPT BioRobotics Newsroom
BTIG Maintains PROCEPT BioRobotics(PRCT.US) With Hold Rating
Wells Fargo Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Raises Target Price to $112
PROCEPT BioRobotics Initiated at Overweight by Morgan Stanley
PROCEPT BioRobotics Analyst Ratings
Morgan Stanley Initiates PROCEPT BioRobotics(PRCT.US) With Buy Rating, Announces Target Price $105
Leerink Partners Sticks to Their Buy Rating for PROCEPT BioRobotics (PRCT)
Jefferies Initiates PROCEPT BioRobotics(PRCT.US) With Hold Rating, Announces Target Price $95
BofA Securities Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Announces Target Price $104
PROCEPT BioRobotics Analyst Ratings
Truist Financial Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Announces Target Price $105
Leerink Partners Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Raises Target Price to $103
A Quick Look at Today's Ratings for PROCEPT BioRobotics(PRCT.US), With a Forecast Between $99 to $103
Strong Financial Performance and Growth Potential Drive Buy Rating for PROCEPT BioRobotics
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), PROCEPT BioRobotics (PRCT) and Travere Therapeutics (TVTX)
A Quick Look at Today's Ratings for PROCEPT BioRobotics(PRCT.US), With a Forecast Between $75 to $99
PROCEPT BioRobotics Analyst Ratings
TD Cowen Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Maintains Target Price $99
Truist Financial Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating
Piper Sandler Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Maintains Target Price $75
Piper Sandler Sticks to Its Buy Rating for PROCEPT BioRobotics (PRCT)